2026-08-10T01:28:36Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/231142024-11-28T15:57:51Zcom_20.500.12105_2173com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19597col_20.500.12105_16938col_20.500.12105_16962col_20.500.12105_16973col_20.500.12105_16987
Repisalud
author
Hernando, Jorge
author
Roca-Herrera, Maria
author
García-Álvarez, Alejandro
author
Raymond, Eric
author
Ruszniewski, Philippe
author
Kulke, Matthew H
author
Grande, Enrique
author
García-Carbonero, Rocio
author
Castellano, Daniel
author
Salazar, Ramón
author
Ibrahim, Toni
author
Teule, Alex
author
Alonso, Vicente
author
Fazio, Nicola
author
Valle, Juan W
author
Tafuto, Salvatore
author
Carmona, Ana
author
Navarro, Victor
author
Capdevila, Jaume
2024-09-16T08:17:09Z
2024-09-16T08:17:09Z
2023-07
Eur J Cancer . 2023 :188:39-48
10.1016/j.ejca.2023.04.013
1879-0852
European journal of cancer (Oxford, England : 1990)
37196483
https://hdl.handle.net/20.500.12105/23114
PURPOSE: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we combine the differential toxicities by sex in five published clinical trials with multikinase inhibitors (MKI) in gastroenteropancreatic (GEP) NET. METHODS: We performed a pooled univariate analysis of reported toxicity in patients treated in five phase 2 and phase 3 clinical trials with MKI in the GEP NET setting: sunitinib (SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT). Differential toxicities between male and female patients were evaluated considering relationship with study drug and different weights of each trial by random effect adjustment. RESULTS: We found nine toxicities which were more frequent in female patients (leukopenia, alopecia, vomiting, headache, bleeding, nausea, dysgeusia, neutrophil count decreased and dry mouth) and two toxicities being more frequent in male patients (Anal Symptoms and Insomnia). Asthenia and diarrhoea were the only severe (Grade 3-4) toxicities more frequent in female patients. CONCLUSIONS: Sex-related differences in toxicity with the MKI treatment require targeted information and individualised management of patients with NET. Differential reporting of toxicity should be promoted when clinical trials are published.
eng
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
research article